Clinical and oncological effects of triplet chemotherapy followed by radical esophagectomy for resectable esophageal cancer associated with unfavorable prognostic factors

• Published in: Surgery today (Tokyo, Japan) Japan), 2014-07, Vol.44 (7), p.1273-1281
• Main Authors: Shimoji, Hideaki, Kinjo, Tatsuya, Karimata, Hiroyuki, Nagahama, Masayoshi, Nishimaki, Tadashi
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Chemotherapy, Adjuvant; Cohort Studies; Doxorubicin - administration & dosage; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - mortality; Esophageal Neoplasms - surgery; Esophagectomy - methods; Female; Fluorouracil - administration & dosage; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds - administration & dosage; Original Article; Prognosis; Prospective Studies; Surgery; Surgical Oncology; Survival Rate
• ISSN: 0941-1291; 1436-2813
• DOI: 10.1007/s00595-013-0700-8

Purposes The purpose of this study was to evaluate the hypothesis that the survival of patients undergoing R0 resection after triplet chemotherapy for resectable esophageal cancer with unfavorable prognostic factors (Category 3) would be similar to that of patients undergoing esophagectomy for esophageal cancer without such factors (Category 1). Methods Patients with Category 3 tumors were assigned to receive triplet chemotherapy consisting of 5-fluorouracil, doxorubicin and nedaplatin (FAN) followed by radical esophagectomy. The outcomes of the bimodality treatment for Category 3 patients ( n  = 25) were compared with those of Category 1 patients ( n  = 41) in a prospective cohort study. Results Grade 3 or higher toxicity developed during chemotherapy in 32 % of the Category 3 patients, with no treatment-related deaths. No significant difference was detected in the surgery-related mortality and morbidity rates between the two groups. The recurrence-free survival was significantly worse in Category 3 than in Category 1 patients ( p  = 0.002), although the overall survival was not significantly different ( p  = 0.085) between the two groups in cases of R0 resection (5-year survival rates: 34.4 vs. 66.5 %). Conclusions Although FAN chemotherapy followed by radical esophagectomy can be safely performed, this treatment modality may not have sufficient power to cure Category 3 disease.